• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Dysgerminoma

Dysgerminoma - 4 Studies Found

Completed : Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)
: Dysgerminoma
: 2005-09-13
: Drug: Darbepoetin alfa
Completed : Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
:
  • Germ Cell Tumor
  • Nonseminomatous Germ Cell Tumor
  • Seminoma : 2017-05-16
    :
    • Drug: Durvalumab 1500 mg by IV

Terminated : Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer
:
  • Ovarian Dysgerminoma
  • Recurrent Malignant Testicular Germ Cell T
    : 2002-08-05
    :
    • Drug: imatinib mesylate Given

Completed : Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
:
  • Bladder Cancer
  • Brain and Central Nervous System Tumors
  • Bre
    : 2006-04-11
    :
    • Drug: lapatinib Other Names:

Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.